Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500

Summary

This is a placebo-controlled double-blind crossover comparative study of KW-6500 in Parkinson's disease patients with motor response complications on levodopa therapy. The efficacy of KW-6500 is evaluated using the change of UPDRS part III score at double blind period after 12 weeks subcutaneous self-injections.

Timeline

Start

2010-01

Primary completion

2010-10

Completion

2010-10

Drugs

Indications